PARP1 and breast carcinoma: Although treating patients with advanced breast cancer carrying pathogenic variants of BRCA with platinum-based chemotherapy is more advantageous than PARP inhibitors according to our analyses, the results need further verification in a sizable RCT that includes direct comparisons.